The Inside Story on Peptides: 16 Years, Real Cases, and What the FDA Just Did

The compounds reshaping longevity medicine — the ones your biohacker friends are injecting — most of them started in a Russian military lab. And the Doctor I'm talking with has been using them clinically for over a decade. This is the perspective you won't get from a podcast that's never seen a DEXA scan.

The FDA Just Shifted the Landscape

An FDA advisory committee recently voted to recommend six peptides for legal compounding. That list includes BPC-157, Epithalon, TB-500, and C-Max. The vote is non-binding — but it's the clearest regulatory signal that the peptide landscape is shifting toward legitimacy. Stark's Doctor, Dr. Alice, has been running clinical peptide protocols at Stark for over 10 years — longer than most people have even heard the word peptide.

The origin of peptide research didn't come from Silicon Valley biohackers. It came from the Russians, who were exploring these compounds in the 1980s to enhance their soldiers and athletes. When Dr. Alice brought peptide research into medical school in 2015, her instructors were confused and dismissive. She assumed that meant peptides were fringe. The FDA vote suggests otherwise.

The GLP-1 Data Point Nobody Is Putting in Their Ads

GLP-1 agonists — Ozempic, tirzepatide, and their successors — are currently the highest-profile peptides in mainstream medicine. At Stark, the reason we haven't adopted GLP-1s as blanket therapy comes down to one piece of data: the DEXA scan.

DEXA scans measure body composition with precision. When Stark students using GLP-1s get their scans back, the team sees it consistently: 10 pounds of lean mass lost. That is years of training erased. It is very difficult to put 10 pounds of lean mass back on — particularly for women, and particularly as you age. This is the number nobody is putting in the semaglutide ads, and it's the reason clinical supervision matters before and during any GLP-1 protocol.

There are exceptions. Dr. Alice has seen remarkable transformations — one male student lost 25 pounds of fat mass without losing any lean mass, and actually gained muscle. But he was also on TRT, eating high protein, doing sophisticated strength training, and sleeping exceptionally well. When everything is in place, outcomes can be exceptional. When they're not, the downsides are significant and hard to reverse.

The GLP-1 Hierarchy — Where We Are Today

Ozempic is a single GLP-1 agonist. Tirzepatide is dual-acting (GLP-1 + GIP). Retatrutide is triple-acting. A quadruple-acting peptide is in development. Dr. Alice describes this evolution like blood pressure medications: pharmaceutical companies make incremental improvements, secure new patents, and cycle through generations. The compounding market allows access to these compounds outside the branded drug framework — which is exactly what the FDA vote just addressed.

BPC-157, TB-500, and What Clinical Reality Looks Like

BPC-157 is one of the most discussed peptides right now. It's not FDA-approved, and clinical results are genuinely mixed. Injectable, oral, and liposomal formulations all produce different outcomes. Dr. Alice has seen dramatic successes — including a student injured out of state who was overnighted BPC-157, TB-500, collagen, and vitamin C and whose out-of-state doctors reported remarkable recovery progress. She's also seen cases where there was no measurable benefit.

This is the honest reality of peptide medicine as it exists today: not a guarantee, not a scam, but a frontier that requires clinical rigor, individual assessment, and monitoring — not a mail-order protocol. At Stark, peptide use is part of a coordinated medical program, not an isolated decision.